Compare AIMD & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIMD | NCEL |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 10.0M |
| IPO Year | N/A | N/A |
| Metric | AIMD | NCEL |
|---|---|---|
| Price | $1.95 | $2.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 195.4K |
| Earning Date | 03-06-2026 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,037.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 178.19 | N/A |
| 52 Week Low | $1.61 | $1.89 |
| 52 Week High | $4.75 | $7.64 |
| Indicator | AIMD | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | N/A |
| Support Level | $1.86 | N/A |
| Resistance Level | $1.97 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 87.50 | 0.00 |
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.